Gerontologists, practicing ethicists, policymakers, and health practitioners should consider the structural conditions of long-term care that both foster aggression and constrain prevention efforts, according to this commentary.
Pseudomedicine products aimed at treating dementia and cognitive performance have increased in prevalence in recent years.
Researchers identified current gaps in aging and diversity research and identified future directions that research should take.
Computer use, crafting, social activities and video games all seem to improve brain health.
The rates have dropped over the last decade and better education might be one reason why.
A new statement from the American Heart Association warns of link between midlife hypertension and its associated risk for dementia.
Why this physician supports the use of antipsychotics in palliative care.
New research suggests that people without dementia who begin reporting memory issues may be more likely to develop dementia later, even if they currently have no clinical signs. The study is published in the September 24, 2014 online issue of Neurology, the medical journal of the American Academy of Neurology.
On January 26, 1996, the Newtown, PA police and 3 SWAT teams surrounded the du Pont mansion on the Foxcatcher estate, about 15 miles west of Philadelphia. Earlier that day, John du Pont, the chemical company heir, shot and killed his longtime friend, Dave Schultz, 36, an Olympic gold medalist in freestyle wrestling. Armed with several guns, du Pont refused to surrender to police and held up in his mansion. A standoff commenced. It was particularly cold, and after 2 days, the police shut off the power and heat. When Mr. du Pont went outside to investigate, they captured him.
Teams of highly respected Alzheimer’s researchers failed to replicate what appeared to be breakthrough results for the treatment of this brain disease when they were published last year in the journal Science.
Those results, presented online Feb. 9, 2012, suggested that the drug bexarotene (marketed as Targretin®) could rapidly reverse the buildup of beta amyloid plaques (Aβ) – a pathological hallmark of Alzheimer’s disease – in the brains of mice. According to the authors of the 2012 report, drug treatment quickly removed most of the plaques and brought rapid reversal of the pathological, cognitive and memory deficits related to the onset of Alzheimer’s.
